Results 141 to 150 of about 140,103 (295)

Patient‐Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non‐Transfusion‐Dependent β‐Thalassemia Treated in the BEYOND Trial

open access: yesEuropean Journal of Haematology, Volume 117, Issue 1, Page 161-173, July 2026.
ABSTRACT In the phase 2, double‐blind, randomized controlled BEYOND trial (NCT03342404), luspatercept increased hemoglobin levels in patients with non‐transfusion‐dependent β‐thalassemia (NTDT). This study assessed long‐term effects of luspatercept on patient‐reported outcomes (PROs), using data from BEYOND and patients who continued luspatercept ...
Khaled M. Musallam   +12 more
wiley   +1 more source

THE FREQUENCY OF ADRENAL INSUFFICIENCY IN ADOLESCENTS AND YOUNG ADULTS WITH THALASSEMIA MAJOR VERSUS THALASSEMIA INTERMEDIA IN IRAN

open access: gold, 2014
Sara Matin   +6 more
openalex   +2 more sources

PSY154 - ECONOMIC BURDEN OF BETA-THALASSEMIA: LITERATURE REVIEW [PDF]

open access: bronze, 2018
Anna Kotzeva   +4 more
openalex   +1 more source

Renal damages in patients with major β-thalassemia [PDF]

open access: diamond, 2019
Malihe Najafpour   +4 more
openalex   +1 more source

Hemoglobin Nigeria (alpha-81 Ser replaced by Cys):a new variant associated with alpha-thalassemia [PDF]

open access: bronze, 1980
GR Honig   +6 more
openalex   +1 more source

The Longitudinal Effect of APOL1 Risk Alleles on Sickle Cell Anemia‐Associated Kidney Function

open access: yesAmerican Journal of Hematology, Volume 101, Issue 6, Page 1341-1350, June 2026.
ABSTRACT Progressive kidney injury is a major cause of morbidity and mortality in sickle cell anemia (SCA). The high risk APOL1 G1/G2 variants contribute to the development of kidney disease in individuals of African ancestry, including those with SCA.
Sara R. Rashkin   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy